Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.

IPO T1APMD

Investing.com 2mo ago

Apnimed prices IPO at $16 per share, raising $192 million

IPO T3APMD

Investing.com 2mo ago

Form S-1 Apnimed For: 30 July

IPO T3APMD

Yahoo Finance 2mo ago

Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development

IPO T2APMD

Bloomberg Markets 2mo ago

Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO

Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.

IPO T1APMD

Seeking Alpha News 3mo ago

Apnimed Seeks IPO For OSA Treatment Commercialization

IPO T2APMD

Seeking Alpha 3mo ago

Braveheart, Attovia, Apnimed join gene therapy firm Scribe in July IPO rush

IPO T2APMD

Bloomberg Markets 3mo ago

Shionogi-Backed Apnimed Files for IPO to Fund Sleep Apnea Drug

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized.

IPO T1APMD

APMD news alerts

Get an alert by email or push when a new headline mentions APMD.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.